Effect of hospital volume on outcomes of total hip arthroplasty: A systematic review and meta-analysis

Syed Hamza Mufarrih  
*Aga Khan University*, syed.hamza@aku.edu

Muhammad Owais Abdul Ghani  
*Vanderbilt University Medical Center, Nashville, USA.*

Russell S. Martins  
*Aga Khan University*, russell.martins@scholar.aku.edu

Nada Qaisar Qureshi  
*Aga Khan University*

Sayyeda Aleena Mufarrih  
*Khyber Girls Medical College, Peshawar, Pakistan*

*See next page for additional authors*

Follow this and additional works at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs

Part of the Life Sciences Commons, Orthopedics Commons, and the Surgery Commons

**Recommended Citation**  
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_bbs/857
Effect of hospital volume on outcomes of total hip arthroplasty: a systematic review and meta-analysis

Syed Hamza Mufarrih1*, Muhammad Owais Abdul Ghani2, Russell Seth Martins3, Nada Qaisar Qureshi4, Sayyeda Aleena Mufarrih5, Azeem Tariq Malik6 and Shahryar Noordin7

Abstract

Background: A shift in the healthcare system towards the centralization of common yet costly surgeries, such as total hip arthroplasty (THA), to high-volume centers of excellence, is an attempt to control the economic burden while simultaneously enhancing patient outcomes. The "volume-outcome" relationship suggests that hospitals performing more treatment of a given type exhibit better outcomes than hospitals performing fewer. This theory has surfaced as an important factor in determining patient outcomes following THA. We performed a systematic review with meta-analyses to review the available evidence on the impact of hospital volume on outcomes of THA.

Materials and methods: We conducted a review of PubMed (MEDLINE), OVID MEDLINE, Google Scholar, and Cochrane library of studies reporting the impact of hospital volume on THA. The studies were evaluated as per the inclusion and exclusion criteria. A total of 44 studies were included in the review. We accessed pooled data using random-effect meta-analysis.

Results: Results of the meta-analyses show that low-volume hospitals were associated with a higher rate of surgical site infections (1.25 [1.01, 1.55]), longer length of stay (RR, 0.83[0.48–1.18]), increased cost of surgery (3.44, [2.57, 4.30]), 90-day complications (RR, 1.80[1.50–2.17]) and 30-day (RR, 2.33[1.27–4.28]), 90-day (RR, 1.26[1.05–1.51]), and 1-year mortality rates (RR, 2.26[1.32–3.88]) when compared to high-volume hospitals following THA. Except for two prospective studies, all were retrospective observational studies.

Conclusions: These findings demonstrate superior outcomes following THA in high-volume hospitals. Together with the reduced cost of the surgical procedure, fewer complications may contribute to saving considerable opportunity costs annually. However, a need to define objective volume-thresholds with stronger evidence would be required.

Trial registration: PROSPERO CRD42019123776.

Keywords: Total hip arthroplasty, Hospital volume, THA, Low-volume hospitals vs. high-volume hospitals, THA outcomes, Total hip replacement

* Correspondence: hamzamufarrih@live.com
1Department of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan
Full list of author information is available at the end of the article
Background
Total hip arthroplasty (THA), a remarkably successful, safe, and cost-effective treatment for pain and joint dysfunction resulting from end-stage arthritis [1–4], is performed annually for approximately one million patients worldwide, with over 300,000 patients in the USA [5]. These numbers are expected to rise 174% by 2030, primarily driven by aging populations and an increase in life expectancy [5]. Although arthroplasty has shown promising results in reducing pain severity and improving the joint function of the patients, there is still room for improvement in terms of shortening length of hospital stay (LOS) and decreasing risk of postoperative dislocation, peri-prosthetic fracture, and infection to effectively lower the overall cost of hip arthroplasty and revision rates.

Since the inception of modern THA in 1960 [6], various studies have identified several factors that may affect the outcomes of the surgery. These include patient-related factors such as age [7, 8], gender [9, 10], elevated body mass index [11], number of comorbid conditions [12, 13], American Society of Anesthesiologist (ASA) grade [14], neuropsychiatric disorders [15, 16], and technical-factors such as surgical complexity, implant type, head size, and bearing surfaces [17–20].

Recently, the concept of hospital factors has surfaced. It has been shown that hospitals performing more treatments of a given type exhibit better outcomes than hospitals performing fewer. This is called the “volume-outcome” relationship and several studies have observed this effect in total hip arthroplasty, where the outcomes of hip arthroplasty in hospitals which perform a higher number of hip arthroplasty procedures annually are better than hospitals which perform a fewer number [21–23]. As the current healthcare system endeavors to implement value, centralization of common yet costly surgeries, such as THAs, to high-volume centers of excellence may be an effective way to control the economic burden. While several studies have investigated the hospital volume relationship, no systematic review or meta-analysis has been conducted to pool the results. In our study, we combine data from all published studies to study the differences in outcomes of hip arthroplasty in high-volume and low-volume hospitals.

Methods
The review follows the PRISMA guidelines [24].

Table 1 Eligibility Criteria for studies included in the review

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1) Studies that compared the outcomes of low-volume hospitals (LVH) and high-volume hospitals (HVH) for hip arthroplasty.</td>
<td>1) Less than 25 cases</td>
</tr>
<tr>
<td>2) Articles in which the study population was undergoing primary or revision THA.*</td>
<td>2) Greater than 10% patients lost to follow-up</td>
</tr>
<tr>
<td>3) Reported outcomes included perioperative morbidity/complication, in-hospital mortality, postoperative mortality within 1 year, readmission, length of stay (LOS), and cost of surgery.</td>
<td>3) Measured outcomes not reporting significance of results</td>
</tr>
<tr>
<td></td>
<td>4) Studies not available in English</td>
</tr>
</tbody>
</table>

*Studies reporting relationships between hospital volume and hip arthroplasty following trauma/malignancy were excluded.
Synthesis of results
The meta-analysis was performed using RevMan Version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark) for calculating pooled summaries and generating forest plots. Meta-analysis was only possible if the retrieval of sufficient data from the study or through contact with the author had been successful.

There was considerable heterogeneity among the studies in the cutoffs for categorizing hospital volume as low or high. To account for this, and other variations including the fact that studies were performed in different regions of the world, with differences in age groups and technical surgical protocols, we decided to use the Mantel-Haenszel random-effect model to report the risk-ratio and heterogeneity ($I^2$) in our analysis.

The random effect model assumes that the effect size is obtained from a population of effect sizes. Therefore, the effect size is derived from the sampling of an effect size at random, in addition to measurement error (the inverse function of the sample size). Because the random-effects model considers the two sources of error in effect size, they are able to yield a larger error term and less statistical power than fixed-effect models. However, one could benefit from random effect models over fixed-effect models because of its ability to generalize the result to a broader universe of studies. These models specifically account for the heterogeneity of studies through a statistical parameter representing the inter-study variation. For the parameters recorded in our review, the random-effect model was preferred for the pooling of the data in the meta-analysis.

For pooling means, we used the standard mean difference (SMD) instead of mean difference, so that we could standardize the results of all studies to a uniform scale. This was necessary as the mean values varied widely from region to region (For example, the mean length of stay in studies from Japan ranged between 25–60 days postoperatively while the mean length of stay in studies in the USA ranged between 4–10 days).

---

**Fig. 1** PRISMA flow diagram for study selection
The use of standard mean difference expresses the size of the intervention effect in each study relative to the variability observed in the study, rather than comparing it with other studies. Therefore, the net effect determined is the pooled summary of the standard mean difference among each individual study, rather than a comparison with the means of other studies. This was used to compare the difference in length of stay and cost of surgery between HVH and LVH. The length of stay was reported by many studies in different parts of the world, and the protocols they use for their surgeries vary vastly. Similarly, the cost of the surgeries was reported using different currencies at different times. Such a model is useful to pool studies with such vast heterogeneity.

We decided to pool surgical site infections as per the CDC definition of surgical site infection, 1999 [25].

Quality appraisal of studies
We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system to evaluate the quality of studies in our review [26].

Results
This work has been reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) [27] and AMSTAR (Assessing the methodological quality of systematic reviews) Guidelines [28].

Study selection
A preliminary total of 1342 studies were identified from Google Scholar, PubMed, and Cochrane library. The removal of duplicates yielded 982 studies. Through screening of titles and abstracts, 93 studies which fulfilled the inclusion criteria were extracted. Following full-length reviews, 49 studies were excluded based on the exclusion criteria. Forty-four studies were included in the qualitative review, and only 31 were included in the meta-analysis. The process of study selection has been summarized in the PRISMA flow diagram (Fig. 1: PRISMA flow diagram for study selection).

Study characteristics
A total of 44 studies were included in the review. Forty-two studies were retrospective studies where longitudinal data was collected over a certain period of time from pre-existing databases, while 2 were prospective. Six studies had included both primary THA and revision THA [23, 29–33]. The remaining 38 studies were focused solely on primary THA. Data from revision surgeries is described in Additional file 4. Only data from primary THA was used to pool results in our analyses. Twenty-four of the 44 studies were conducted in the USA while the remaining were contributed by 11 unique countries (details in Additional file 1). The average age of the patient population was 67.7 years (reported by 28 studies). Overall, 43.3% of the patients were male and 56.7% of the patients were female (reported by 34 studies). Details of the study characteristics are summarized in Additional file 1. A total of 38 studies had adjusted for covariates (details in Additional file 2). Patient comorbid conditions including diabetes mellitus, obesity, dyslipidemia, chronic kidney disease, heart disease, hypothyroidism, chronic obstructive pulmonary disease, peripheral vessel disease, and depression were only reported by 13 studies (details in Additional file 5).

Outcomes and findings
These studies include data from 1988 to 2011. Detailed results of data extraction on reported outcomes are presented in Additional file 3.

Surgical-site infections
A total of 8 studies [31, 34–40] totaling 200,950 hip arthroplasties were pooled to compare the rates of...

![Fig. 2](image-url)
surgical-site infections SSI 1-year postoperatively between LVH and HVH. We observed that surgical site infections were more frequently observed in LVH with a risk ratio (RR) of 1.25 (CI [1.01, 1.55]; $I^2 = 59\%$, $p$ value = 0.04) (Fig 2 comparison of surgical site infections (1-year postoperatively) between low-volume and high-volume hospitals).

Four studies, which could not be added to the pooled-analysis, also compared postoperative incidence of SSIs. Two of the studies (Kaneko, et al. [41] and Soohoo et al. [42]) reported a significantly higher rate of SSIs following THA at low-volume hospitals while two studies (Huang et al. [43]. and Makela et al. [44]) reported no significant difference between low-volume and high-volume hospitals.

Cost of surgery
Six studies [34, 36, 43, 45–47] totaling 129,893 hip arthroplasties were pooled to compare the cost of Primary THA in LVH vs. HVH. Based on the results of the random meta-analysis model, we found that the cost of surgery is significantly higher in LVH with SMD of 3.44 (CI [2.57, 4.30]; $I^2 = 100\%$, $p$ value < 0.00001) (Fig. 3: comparison of cost of surgery between low-volume and high-volume hospitals).

Three studies reporting differences in the cost of surgery could not be included in the meta-analysis. Courtney et al. [48] reported that THA procedures performed at HVH had significantly lower total mean hospital-specific charges. Frisch et al. [49] and Lavernia et al. [50] found no significant difference between mean hospital charges for THA performed at LVH and HVH.

Length of postoperative hospital stay
A total of 9 studies [36, 37, 41, 43, 45, 46, 51–53] totaling 232,691 hip arthroplasties were pooled to compare the length of postoperative stay in LVH vs. HVH. Based on the results of the random meta-analyses model, we found that postoperative stay was significantly longer in LVH with a SMD of 0.83 (CI [0.48, 1.18] $I^2 = 100\%$, $p$ value = 0.00001) (Fig. 4: comparison of length of stay between low-volume and high-volume hospitals).

Three studies reporting length of stay in low-volume and high-volume hospitals could not be included in the meta-analysis. Doro, et al. [23], Makela et al. [44], and Judge et al. [54] reported increased LOS in LVH as compared to VH VH.

Complications during index hospitalization
A total of 5 studies [36, 37, 40, 43, 55] totaling 36,159 hip arthroplasties were pooled to compare the complications during index hospitalization between LVH and HVH. Based on the results of the random meta-analysis
model, we found that there is no significant difference in rates of index hospitalization complications between LVH and HVH, with RR = 0.90 (CI [0.49, 1.64] $I^2 = 91\%$, $p$ value = 0.73) (Fig. 5: comparison of complications during index hospitalization between low-volume and high-volume hospitals).

Complications within 90 days postoperatively
A total of 3 studies [42, 55, 56] totaling 74,409 hip arthroplasties were pooled to compare the rates of complications 90 days postoperatively in LVH with HVH. Based on the results of the random meta-analyses model, we found that there is a significantly higher chance of 90-day complications in LVH as compared to HVH (RR = 1.80 (CI [1.50, 2.17] $I^2 = 52\%$, $p$ value < 0.00001) (Fig. 6: comparison of complications 90 days postoperatively between low-volume and high-volume hospitals).

Although not included in the meta-analysis, Solomon et al. and Katz (2001) et al. also report a higher incidence of postoperative complications in LVH compared to HVH.

Revision hip arthroplasty at 1-year postoperative
A total of 5 studies [36, 37, 40, 42, 57] totaling 361,440 hip arthroplasties were pooled to compare the rates of revision THA between LVH and HVH. Based on the pooled analysis, no significant difference was observed between rate of revisions for surgeries performed in LVH and HVH 1 year postoperatively; RR = 1.27 (CI [0.98, 1.65] $I^2 = 73\%$, $p$ value = 0.07) (Fig. 7: comparison of revision hip arthroplasty 1 year postoperatively between low-volume and high-volume hospitals).

Revision hip arthroplasty at 3 years postoperative
Five studies [22, 57–60] totaling 509,155 hip arthroplasties were pooled. No significant difference was observed between rate of revisions for surgeries performed in LVH and HVH; RR = 1.18 (CI [0.86, 1.62] $I^2 = 97\%$, $p$ value = 0.31) (Fig. 8: comparison of revision hip arthroplasty 3 years postoperative between low-volume and high-volume hospitals). In addition to this, Pamilo et al. [51], Makela et al. [44], and Manley et al. [61] also reported that there was no significant association between revision rates and hospital volume. In contrast, Judge et al. [54] reported a higher hazard ratio of revision arthroplasty 5 years postoperatively for HVH vs. LVH.

30-day mortality
Three studies [21, 33, 62] totaling 140,656 hip arthroplasties were pooled to compare the mortality rates within 30 days postoperatively between LVH and HVH. Based on the results of the random meta-analysis model, we found a significantly higher mortality rate in LVH, RR = 2.33 (CI [1.27, 4.28] $I^2 = 93\%$, $p$ value = 0.006) (Fig. 9: comparison of 30-day mortality between low-volume and high-volume hospitals).
volume and high-volume hospitals (study by Taylor et al. reported findings from 1994 and 1995 separately).

90-day mortality
A total of 4 studies [35–37, 40] totaling 58,688 hip arthroplasties were pooled to compare mortality rates within 90 days postoperatively between LVH and HVH. Based on the results of the random meta-analysis model, we found a significantly higher mortality rate in LVH, RR = 1.26 (CI [1.05, 1.51] $I^2 = 0\%$, $p$ value = 0.01) (Fig. 10: comparison of 90-day mortality between low-volume and high-volume hospitals).

1-year mortality
Four studies, [36, 37, 62, 63] totaling 13,203 hip arthroplasties were pooled to compare mortality rates within 1 year postoperatively between LVH and HVH. Based on the results of the random meta-analysis model, we see that there is a significantly higher mortality rate in LVH, RR = 2.26 (CI [1.32, 3.88] $I^2 = 72\%$, $p$ value = 0.003) (Fig. 11: comparison of 1-year mortality between low-volume and high-volume hospitals).

A few studies reporting postoperative mortality as an outcome could not be included in the meta-analysis. Two studies (Lavernia et al. [50] and Laura et al. [55]) stated no statistically significant difference in mortality rates between LVH and HVH. However 7 studies (Hughes et al. [64], Solomon et al. [65], Sharkey et al. [66], Riley et al. [67], Judge et al. [54], Chien et al. [68], and Doro et al. [23]) reported a significant inverse relation between hospital volume and mortality rate.

Postoperative thromboembolic events
Five studies, [35–37, 42] totaling 130,572 hip arthroplasties were pooled to compare the rates post-operative deep venous thrombosis between LVH and HVH. Based on the results of the random meta-analysis model, we found that there was no significant difference in the risk of thromboembolic events 90 days postop; (RR = 1.16, (CI [0.78, 1.72] $I^2 = 78\%$, $p$ value = 0.46) (Fig. 12: comparison of postoperative deep venous thrombosis between low-volume and high-volume hospitals.).

Quality appraisal
All the studies included in this review are observational studies, with 42 retrospective and 2 prospective, which are considered low-grade studies as per the GRADE system guidelines.

Discussion
Few systematic reviews have been conducted in the realm of orthopedic surgery to study the volume-outcome relationship. While knee arthroplasty [69], shoulder arthroplasty [70], spine surgery [71], and hip fractures [72] have been extensively studied, evidence of
the effect of hospital volume on total hip arthroplasty has not been reviewed systematically to our knowledge.

Our review was based on observational studies from several countries around the world with a predominant contribution from the USA. In our review, we found that THAs performed at LVH have a significantly higher risk of surgical site infections, cost of surgery, length of stay, 90-day complications, and mortality (30-days, 90 days, and 1 year) (Table 2).

We found a significantly higher risk of postoperative surgical site infections (SSIs) in LVH compared with HVH. The finding of SSI risk being higher in LVH as compared to HVH may be linked to other factors. Previous literature has reported the association of SSIs with a longer length of hospital stay and has linked a longer length of stay to low-volume hospitals [73, 74]. Another risk factor associated with SSIs is longer operative duration which has also been observed in low-volume hospitals in previous literature [31, 75, 76]. In addition, previous literature suggests that high-volume hospitals may enjoy superior infection prevention measures [77].

Our results, though specific to THA, are in agreement with findings of prior research showing higher risks of SSI in LVH [78, 79].

Our findings also show an inverse relationship between hospital volume and cost of surgery. This may be attributed to greater negotiating power of high-volume hospitals because of higher numbers, greater efficiency, and accelerated care pathways allowing expedited discharge processes and more prudent use of ancillary services at HVH resulting in significant cost savings for the healthcare system and the patient [80].

Length of stay may be a complex variable to dissect as it is a combined reflection of pre-operative, intraoperative, and postoperative care. Previous literature has reported associations among operative time, postoperative complications, and length of stay [81–83]. Though we did not find a significant difference between the postoperative complications in HVH and LVH during their hospital stay in our study, the key factors underlying this complex relationship are potentially related to the superior healthcare provision capacity of HVH including availability of special care facility, infrastructure, specialist medicine care, physiotherapy, pain control anesthesia teams, and other resources during all stages of care and health economy of the country the study was conducted in [35, 84]. This enables the hospitals to be better equipped to deal with problems before they escalate to serious complications [85, 86]. Although several intraoperative factors may also play a role in determining the length of stay between HVH and LVH, this has not been studied in detail.

Although our findings show no significant difference between complications during the hospital stay, complications
at 90 days were reported to be significantly higher in LVH when compared to HVH. Soohoo [42] studied this extensively and concluded that patient and surgeon factors heavily influenced the risk of developing complications. Patient factors associated with higher 90-day complications included male gender, higher Charlson comorbidity score, comorbid conditions such as diabetes and rheumatoid arthritis [42]. While these may not be under the control of the hospital, a shorter learning curve [87] in the presence of better resources [85, 86, 88] may allow an increase in the capacity of HVH to be proactive in identifying and resolving issues before they can adversely influence outcomes. Although our results show a higher 90-day complication rate with low-volume hospitals, there is no significant difference in 1-year and 3-year revision rates between LVH and HVH. This may be due to possible loss to follow-up, visit to high-volume hospitals for revisions or mortality (as seen in our findings).

From a monetary perspective, not only are hip replacement surgeries at HVH cost-effective, they also have a greater value per dollar spent in the long run as they are associated with lower rates of complications, especially surgical site infections. SSIs result in significant losses with up to three-fold cost increase after orthopedic surgeries [89]. This is particularly alarming as the rates of surgical site infections in the USA are on the rise [5, 90–92] and reimbursements are being reduced or denied [93]. Lower rates of 90-day complications are not only better outcomes, but also saves the costs of readmission. Additionally, HVH may have room to negotiate costs with suppliers due to their large volumes. This translates into decreased costs which benefit the patients and the healthcare system.

In contrast, longer length of stay associated with LVH following THA procedures leads to a significant overall increase in expenditure. In total, around 300,000 THA procedures are carried out annually in the USA [94]. Up to 35% (105,000) of these are carried out in LVH [35, 95]. Given that the cost of 1 day of in-patient stay at a hospital in the USA is approximately $2500 [96], each additional day of stay is an additional annual expenditure of $262,500,000. This is excluding additional costs incurred due to the higher rates of SSI and other short-term (90-day post-THA) complications associated with having THA at LVH.

Although there is much debate on the influence of experience of the surgeon and outcomes [97, 98], lower mortality rate at 30 days, 90 days, and 1-year postoperatively in HVHs following hip arthroplasty may be because health care professionals including doctors and staff may have more experience and skill at HVH, with highly evolved and efficient processes of patient care (such as tailored diagnostic and treatment algorithms or guidelines), leading to better patient outcomes [99, 100]. In addition to this, the larger workforce and more system-level resources to use in patient care allow HVHs to tackle unanticipated complications at all stages of care [99].

The better outcomes observed in HVH may best be explained by two popular hypotheses which contribute to positive feedback. First, “practice makes perfect”
which means hospitals develop more effective skills as they treat more patients \[100\] and second “selective referral” where physicians and hospitals with better outcomes receive more referrals subsequently acquiring larger volumes \[101\].

### Limitations

There are several caveats in our study. We were not able to review the intra-operative factors and the functional rehabilitation of patients for comparison between LVH and HVHs. This was because no studies have compared these variables among LVH and HVHs. Additionally, the hospital volume cutoff is not uniform across studies. Katz \[35\] used < 10 procedures per year as the cut-off, while Laucis \[102\] set < 100 cases per year as LVH. This could be due to the rising popularity of arthroplasty to treat end-stage osteoarthritis where the number of THA and TKA increased from 343,000 in 2000 to 851,000 in 2012 and is further on the rise. Hospitals now perform this procedure more frequently, and understandably, the cut-offs have been raised over time as observed in more recent studies. Studies have been conducted in 12 unique countries and variations in volume thresholds may have been contributed by economical, logistic, and disease burden differences. Lastly, our review is based on observational studies. Conducting a randomized control trial (RCT) may have ethical and logistical barriers. Even after 30 years of the first study comparing the outcomes of THA in LVH and HVH, no RCT has been reported. There is a need for stronger evidence, including prospective cohorts, to re-visit this important topic using larger datasets to define objective volume-thresholds/benchmarks.

### Conclusion

Our analysis shows that total hip arthroplasties performed at low-volume hospitals have significantly higher surgical site infection rates, length of stay, cost of surgery, 90-day complications, and mortality rates (30 days, 90 days, and 1 year) compared with high-volume hospitals. Randomized controlled trials and prospective studies should be conducted to assess differences in functional outcomes and intra-operative factors between low-volume and high-volume hospitals using standardized cut-offs for low- and high-volume hospitals.

### Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13018-019-1531-0.

- **Additional file 1.** Study characteristics.
- **Additional file 2.** Covariate adjustment.
- **Additional file 3.** Findings from each study (extracted data).
- **Additional file 4.** Table S4. Hospital Volume Thresholds and Outcomes in Studies of Primary Total Hip Arthroplasty (pTHA).
- **Additional file 5.** Comorbidities reported across studies.
Abbreviations
ASA: American Society of Anesthesiologists; HVH: High-volume hospital; 
LOS: Length of stay; LVH: Low-volume hospital; RR: Risk ratio; SMD: Standard 
mean difference; SSI: Surgical site infection; THA: Total hip arthroplasty

Acknowledgements
None

Authors’ contributions
SHM contributed to the conceptualization, formal analysis, methodology, 
project administration, visualization, and writing—original draft. MAOG 
contributed to the data curation, methodology, and validation. RSM 
contributed to the data curation, visualization, writing—review and 
editing. SAM contributed to the conceptualization and data curation. ATM 
contributed to the validation, visualization, writing—review and editing. SN contributed to 
the conceptualization, supervision, and writing—review and editing. All authors read and approved the final manuscript.

Funding
No funding received

Availability of data and materials
The datasets used and/or analysed during the current study are available 
from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study is a systematic review hence ethics approval was waived. The 
study is registered with Research Registry: reviewregistry730.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1. Department of Biological and Biomedical Sciences, Aga Khan University, 
Karachi, Pakistan. 2. Department of Pediatric Surgery, Vanderbilt University 
Medical Center, Nashville, Tennessee, USA. 3. Medical College, Aga Khan 
University, Karachi, Pakistan. 4. Medical College of Medicine, Aga Khan 
University, Karachi, Pakistan. 5. Medical College, Khyber Girls Medical College, Peshawar, 
Pakistan. 6. Department of Orthopedics, Ohio State University, Columbus, Ohio, 
USA. 7. Department of Orthopedic Surgery, Aga Khan University, Karachi, 
Pakistan.

Received: 29 August 2019 Accepted: 19 December 2019 
Published online: 27 December 2019

References
of patients report long-term pain after total hip or knee replacement for 
osteoarthritis? A systematic review of prospective studies in unselected 
The effect of BMI on 30 day outcomes following total joint arthroplasty. J 
3. Loth FL, Giesinger JM, Giesinger K, MacDonald DJ, Simpson AHR, Howie CR, 
et al. Impact of comorbidities on outcome after total hip arthroplasty. J 
factors for periprosthetic joint infection and postoperative mortality following 
total hip arthroplasty in Medicare patients. JBJS. 2017;99(9):394–400.
5. Pugely AJ, Callaghan JJ, Martin CT, Cram P, Gao Y. Incidence of and risk 
factors for 30-day readmission following elective primary total joint 
arthroplasty: analysis from the ACS-NSQIP. J Arthroplasty. 2013;28(9): 
1499–504.
primary total hip arthroplasty in the Medicare population. J Arthroplasty. 
Survival, Revision Causes, and Patient-reported Outcome. Syddansk 
Universitet; 2016.
8. Singh SP, Bhalodhya HP. Head size and dislocation rate in primary total hip 
Head Size on Dislocation Rates Following Total Hip Arthroplasty. Hip Pelvis. 
primary total hip arthroplasty in the Medicare population. J Arthroplasty. 
11. Crous DL, Leonard PS, Boudreau G, McDonald JT. Associations between 
provider and hospital volumes and postoperative mortality following total 
hip arthroplasty in New Brunswick: results from a provincial-level cohort 
12. Le Cossec C, Colas S, Zureik M. Relative impact of hospital and surgeon 
procedure volumes on primary total hip arthroplasty revision: a nationwide 
13. Doro C, Dimick J, Wainess R, Upchurch G, Urquhart A. Hospital volume and 
inpatient mortality outcomes of total hip arthroplasty in the United States. J 


